In this multi-centre, randomized trial, we compared the safety and efficacy of Diprifusor™ TCI with manually controlled infusion (MCI) of propofol for anaesthesia. With approval, 123 adult male and female patients were studied. Firstly, each investigator anaesthetized five patients to familiarize themselves with Diprifusor™ TCI. In Stage 2, 98 patients were randomized to receive propofol-based anaesthesia via TCI or MCI. Adjuvant drugs, airway management and monitoring were managed at the discretion of the anaesthetist. Results are presented as mean (SD). Induction times were significantly longer [67 (32) vs 54 (17) s] and induction doses were significantly lower [14 (5) vs 16 (4) ml] in the TCI vs the MCI group. Recovery times and total doses were not significantly different. There were statistically but not clinically significant differences in mean arterial blood pressure and heart rate. Quality of anaesthesia and ease of control of anaesthesia were similar. We conclude that Diprifusor™ TCI and MCI are similar in terms of safety and efficacy.
Manually controlled infusions of propfol have become popular for induction and maintenance of general anaesthesia. The main reason for propofol's widespread use by infusion is its favourable pharmacokinetic profile, which allows easy titration of anaesthetic depth and rapid recovery from anaesthesia 1 . However, anaesthetists have limited experience with target controlled infusions (TCI) of propofol, especially in the clinical setting.
A TCI system is microprocessor-controlled, and is programmed with pharmacokinetic parameters and infusion control algorithms for a particular drug. The anaesthetist selects a desired blood concentration and the system designs an infusion to achieve that concentration. The Diprifusor™ is a TCI system for the induction and maintenance of anaesthesia using propofol (Diprivan™ 1%, Zeneca Pharmaceuticals). A three-compartment pharmacokinetic model is incorporated into the Diprifusor™ module 2 . The selection of the pharmacokinetic model 3 and the development of the module 4 have been described in detail. The recent release of the Diprifusor™ in Australia and New Zealand makes TCI technology available to clinical anaesthetists. The question is whether TCI devices improve the quality of anaesthesia with propofol.
Previous comparative studies 5-7 demonstrated a preference for TCI by anaesthetists, even though these studies did not use the commercially available integrated pump. In this multi-centre, randomized trial, we compared the safety and efficacy of TCI using the Diprifusor™, incorporated into the Graseby 3500 (Graseby Medical Ltd.) infusion pump, compared with manually controlled infusion of propofol for anaesthesia in surgical patients.
MATERIALS AND METHODS
With Ethics Committee approval and informed consent, we studied 123 male and female patients, aged >18 years, of ASA physical status 1-3, requiring anaesthesia for elective surgery. The following patients were excluded from the study: 1) those who weighed >120% of their ideal weight; 2) those who were pregnant or possibly pregnant; 3) those with an allergy to the trial drugs or constituents; 4) those receiving drugs likely to influence the course of anaesthesia; and 5) those suffering from incapacitating illness or organ dysfunction.
A sample size of 50 patients per group was calculated to provide adequate statistical power to detect a change in the induction time of approximately 20% or 15s (α=0.05, β=0.8).
Investigators were familiar with manually controlled infusion (MCI) but not target controlled infusion (TCI) of propofol. The trial was conducted in two stages. Stage 1 was an open, multi-centre, noncomparative trial. Each investigator anaesthetized five patients using TCI with propofol. This enabled investigators to familiarize themselves with the Diprifusor™. Stage 2 was an open, multi-centre, comparative, randomized trial involving ~20 patients per investigator. Patients were randomized to receive either Diprifusor™ TCI or a manually controlled infusion (MCI) of propofol.
Patients were premedicated according to the anaesthetist's preference. Intravenous access was established and standard anaesthetic monitoring was commenced. Airway management was undertaken as indicated by the procedure. Adjuvant drugs, including nitrous oxide, sedatives, analgesics and muscle relaxants and intravenous fluids were administered at the discretion of the anaesthetist.
In the TCI group, anaesthesia was induced by targeting a propofol blood concentration of 4-8 µg/ml. In the MCI group, anaesthesia was induced with a bolus of propofol from the infusion pump. In both groups, the initial propofol infusion rate was 1200 ml/h. Subsequently, the target propofol blood concentration, or propofol infusion rate, was adjusted by the anaesthetist, according to the patient's responses and the requirements of the surgery. Propofol infusion was ceased near the end of each case at the anaesthetist's discretion.
The induction time was defined as the time (s) from the start of propofol administration until loss of verbal contact. Recovery times were defined as the time(s) from discontinuation of propofol infusion to eye-opening and the time(s) from discontinuation of propofol infusion to orientation to person.
The induction volume was defined as the volume (ml) of propofol administered from the start of propofol administration until loss of response to command. The total volume (ml) of propofol infused and the number of changes in target concentration or infusion rate were also noted. Target concentrations or infusion rates throughout anaesthesia were recorded, as was the predicted propofol blood concentration at eye opening.
The quality of maintenance of anaesthesia was assessed by the anaesthetist as "good" (uncomplicated maintenance), "adequate" (minor problems but easily managed) or "poor" (significant problems). Ease of control of anaesthesia was scored similarly.
The safety of TCI vs MCI was assessed by recording haemodynamic and respiratory parameters, movement during surgery and other adverse events.
Mean arterial blood pressure (MABP) and heart rate (HR) were measured non-invasively and recorded prior to induction of anaesthesia, 2 minutes after insertion of a laryngeal mask airway or endotracheal tube, and at 5 to 10 minute intervals until the discontinuation of propofol infusion. The presence and duration of apnoea was also noted.
At the end of the case, a subjective assessment of haemodynamic instability was made by the anaesthetist and defined as follows: "None"=MABP 60-100 mmHg, HR <100 beats/min; "Occasional hypotension"=occasional MABP <60 mmHg; "Persistent marked hypotension"=persistent MABP <60 mmHg; "Frequent or persistent tachycardia"= HR >100 beats/ min; "Hypertension"=MABP >100 mmHg.
DATA ANALYSIS
One hundred and twenty-three patients were enrolled in the study: 25 patients in Stage 1 and 98 in Stage 2. Only data from Stage 2 of this study are reported. One patient in the TCI group was incorrectly randomized and nine patients in the TCI group were >120% of ideal body weight. Analysis of stage 2 data was performed on an "intention-to-treat" basis.
Primary outcome variables were defined as induction time, induction dose and recovery time. Secondary outcome variables were quality of anaesthesia, ease of control of anaesthesia, target concentrations and infusion rates, numbers of boluses given, MABP and heart rate. Data were compared using Wilcoxon rank-sum tests. Results are presented as mean (SD), unless otherwise specified; P<0.05 was considered statistically significant.
RESULTS
The study groups were similar in terms of age [51 (TCI) vs 47 years (MCI)], weight (72 vs 78 kg), sex (63 female vs 57% male) and pre-induction arterial blood pressure and heart rate. Most patients were ASA physical status II. Benzodiazepine premedication was used in 62% of TCI patients and 55% of MCI patients (P=ns). There were no significant differences between the groups in the use of adjuvant agents during anaesthesia.
Induction time was significantly longer [67 (32) vs 54 (17) s], and the induction dose significantly less [14 (5) vs 16 (4) ml], in the TCI group compared with the MCI group. There were no significant differences in times to eye-opening or orientation (Table 1) .
Target concentrations during maintenance of anaesthesia ranged from 3.3 (1.5) to 4.4 (1.6) µg/ml. Propofol infusion rates ranged from 12 (24) to 56 (18) ml/h. Target concentrations and infusion rates at various points during anaesthesia are presented in Table 2 . The number of changes to the target concentration or infusion rate were similar for the TCI [ The overall quality of maintenance was similar in the TCI and MCI groups. Anaesthesia maintenance was reported as "poor" quality in four of the patients in the MCI group, whereas no such reports were made in the TCI group. The ease of control of anaesthesia was reported as "good" in 96% of the TCI group and 86% of the MCI group (Table 3) .
Mean arterial blood pressure was significantly lower in the TCI group compared with the MCI group at the early (1-9 minutes post-incision) and middle assessments (10-30 minutes post-incision). Heart rate was significantly greater in the TCI group compared with the MCI group at the late assessment (>30 minutes post-incision). However, these differences were not clinically significant (Figure 1 ). Haemodynamic instability was reported in 20% of TCI and 40% of MCI patients ( Table 4 ). The incidence of apnoea was not different between the two groups.
The incidence of movement was very similar between the TCI and MCI groups. On initial skin incision, 4% of TCI patients and 7% of MCI patients moved. During maintenance of anaesthesia, 18% of TCI and 14% of MCI patients moved. These differences were not significant. Four adverse events were reported during the trial. In Stage I, two patients were reported to have mild hypotension and one patient had "flushed skin". In Stage 2, one patient in the MCI group coughed on induction, leading to regurgitation but not aspiration. These events were resolved successfully.
DISCUSSION
In this study we found that propofol-based anaesthesia with Diprifusor™ TCI was similar in terms of safety and efficacy to manually controlled infusion of propofol. Induction times were longer, but induction doses were lower in the TCI group. Recovery times were similar. There were no clinically significant differences in side-effects or anaesthetists' assessments of quality between the two groups.
Longer induction times, with lower induction doses, are consistently reported with TCI compared with MCI when induction target concentrations are 4-6 µg/ml 6, 7 . Bolus induction with propofol typically results in peak blood concentrations which are much greater than the threshold effect-site concentration for induction of anaesthesia. This ensures rapid induction, but potentially leads to haemodynamic instability 8 and apnoea 9 . The aim of target controlled infusions is to achieve the desired blood concentration without "overshoot" 3 , although this results in longer induction times. There was no evidence in this study, however, that TCI resulted in less clinicallysignificant haemodynamic instability or apnoea at induction.
Recovery times were similar in the TCI and MCI groups in our study. This result is consistent with the studies of Russell et al 5 and Struys et al 6 , and confirms the speed with which most anaesthetists become confident with TCI anaesthesia 5 . As the total dose of propofol and adjuvant drugs delivered were similar, it is not surprising that recovery indices were similar. In contrast, Servin et al 7 reported longer recovery times in the TCI group. They attributed their result to a reluctance on the part of their anaesthetists to decrease the target concentration sufficiently towards the end of the case.
The constant and rapidly titratable blood concentrations of propofol achieved with TCI have the potential to prevent movement during anaesthesia in unparalysed patients and reduce awareness, particularly in the post-induction period 10 . In our study, the total volume of propofol administered was similar in the TCI and MCI groups: less propofol was given at induction, but more was given during maintenance in the TCI group. There was no difference in the incidence of movement during surgery and no report of awareness. Other studies have reported less move-ment in the TCI group 5, 7 . Differences in induction dose, use of adjuvant drugs and pattern of propofol administration may account for this disparity.
In this era of cost-containment, the Diprifusor™ will be judged eventually in terms of cost-effectiveness 11 . The volume of propofol delivered by Diprifusor™ TCI and MCI is similar in comparative studies [5] [6] [7] , including ours. Increased familiarity with TCI may result in reductions in propofol use. In addition, a new feature included in the commerciallyavailable device, which predicts the time to responsiveness if the infusion is ceased, may help the anaesthetist to judiciously stop infusion towards the end of the case 12 . This speculation awaits confirmation by a properly designed cost-benefit analysis.
From the clinical anaesthetist's perspective, "ease of control" is an important index of quality in a new device 13 . It is therefore important to establish how Diprifusor™ TCI compares to MCI in terms of the numbers of interventions required. We reported that the number of changes to either the target concentration or infusion rate were similar in the two groups. Overall "ease of control" of anaesthesia, subjectively assessed by the anaesthetist, was also no different between TCI and MCI in our study. Similarly, Newson et al 14 reported that both TCI and MCI required less intervention from the anaesthetist than repeated bolus injections during propofol sedation, and Engbers 15 reported that the Diprifusor™ was easier to use than MCI. In contrast, Servin et al 7 reported fewer interventions in the TCI group. This may, in part, explain the longer recovery times reported.
Although there were statistically significant differences in haemodynamic indices between the TCI and MCI groups, these differences were not clinically significant. This result is consistent with previous reports 5, 7 . Paradoxically however, there was a difference between objective and subjective assessments of haemodynamic stability. Investigators were less likely to report haemodynamic instability in the TCI group than in the MCI group. Anaesthetists were monitoring arterial blood pressure and heart rate continuously, whereas data were only recorded every five to 10 minutes and were time-weighted before analysis. Hence, the anaesthetists may have detected brief periods of haemodynamic instability not included in the objective analysis.
Failure to show a difference between Diprifusor™ TCI and MCI is unlikely to result from deficiencies in the pharmacokinetic model. Inter-individual variation in population pharmacokinetics and pharmacodynamics is much greater than deviations J. HUNT-SMITH, A. DONAGHY ET AL Anaesthesia and Intensive Care, Vol. 27, No. 3, June 1999 between targeted and measured concentrations 16 . It is more likely that experience with propofol-based anaesthesia over many years has taught anaesthetists to use manually controlled infusions successfully and without excessive side-effects. The Diprifusor™ may gain acceptance as a "user-friendly" device which provides additional useful information, such as predicted time to awakening.
In conclusion, we found that propofol-based anaesthesia with Diprifusor™ TCI was similar in terms of safety and efficacy to manually controlled infusion of propofol. Diprifusor™ TCI is a useful alternative to manually controlled infusion of propofol in adult surgical patients. 
